Conditions: Upper GI Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 5
Healthy volunteers: no

Brief summary:
Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: regorafenib
Intervention descriptions: intervention 1: None

Protocol document: